Is Vismodegib available in China?

The original drug Vismodegib (Vismodegib) is not currently on the market in China. Vismodegib is a drug used to treat basal cell carcinoma (BCC) with the trade name Erivedge. Vimodegib was approved for marketing by the U.S. Food and Drug Administration (FDA) in January 2012. It is the first FDA-approved agent targeting the Hedgehog signaling pathway , which is involved in many basal cell carcinomas. Basal cell carcinoma is the most common non-melanoma skin cancer (NMSC), accounting for more than half of all NMSC diagnoses. In July 2013, it was approved by the European Medicines Agency (EMA), who believed that the benefits of vismodegib in patients with locally advanced and metastatic disease have been proven, and that the side effects can be controlled.